Genetic Group Ownership Changes as CVC Completes Exit - InforCapital

CVC Capital Partners has completed the sale of its full stake in Genetic Group, a leading pharmaceutical CDMO based in Italy, for approximately $760 million. The buyers are NB Renaissance and NB Aurora, while the Pavese family, Genetic’s founders, have also increased their ownership.

Genetic Group, headquartered in Fisciano, operates in the research, development, and manufacturing of pharmaceutical products, targeting therapeutic areas such as respiratory, ophthalmic, and oncology. It utilizes advanced technologies including unit-dose Blow-Fill-Seal, Metered Dose Inhalers, nasal sprays, and eye drops. Its products are distributed globally through pharma partnerships and its local channel, Genetic Farma.

CVC originally invested in 2020, supporting the company’s international expansion—from 20 countries to over 40—and backing a new production facility. During CVC’s ownership, revenues more than doubled, and the R&D pipeline was significantly expanded.

This transaction represents a strategic exit for CVC’s Strategic Opportunities II fund and a new phase of growth for Genetic under the leadership of NB Renaissance and Aurora, with continued involvement from the founding family.

The deal remains subject to regulatory approvals.